Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report

~~SECURITIES REGISTERED PURSUANT TO SECTION~~Securities registered pursuant to Section 12(b) ~~OF THE ACT:~~of the Act:

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒

The number of shares outstanding of the Registrant’s Common Stock, $0.01 par value, was 303,757,622 as of ~~May 15,~~August 18, 2023

	March 31,			December 31,			June 30,			December 31,
	2023			2022			2023			2022
	(unaudited)						(unaudited)
ASSETS
Current Assets
Cash	E	335		E	313		€	402		€	313
Accounts receivable		86			62			42			62
Prepaid expenses		93			106			49			106
Total current assets		514			481			493			481

Rent deposit		10			10			10			10
Property and equipment, net of accumulated depreciation of E478 at March 31, 2023 and E475 at December 31, 2022		23			26
Property and equipment, net of accumulated depreciation of €498 at June 30, 2023 and €475 at December 31, 2022								3			26
Right-of-Use Asset		106			133			27			133
Goodwill		6,671			6,671			-			6,671
	E	7,324		E	7,321		€	533		€	7,321

LIABILITIES AND SHAREHOLDERS' DEFICIT
LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT)
Current Liabilities
Accounts payable	E	971		E	213		€	659		€	213
Deferred revenue (Grant)		-			7
Operating lease liability		106			106
Deferred revenue								-			7
Operating Lease Liability								28			106
Non-convertible notes payable and related accrued interest to related parties		11,024			10,461			11,695			10,461
Convertible notes payable and related accrued interest to related parties		61,821			61,243			62,458			61,243
Total current liabilities		73,922			72,030			74,840			72,030

Long Term Liabilities
Debt-Federal Financing Bank		155			156
Debt-Principal Payable to the Federal Financing Bank								144			156
Operating lease liability		4			31			-			31
Total long-term liabilities		159			187			144			187
		74,081			72,217			74,984			72,217

Commitments and Contingencies (Note 3)		-			-			-			-

Shareholders' Deficit
Common stock, U.S. $0.01 par value; 1,200,000,000 shares authorized; issued and outstanding 303,757,622 at March 31, 2023 and at December 31, 2022		2,530			2,530
Preferred stock, U.S. $0.01 par value; 5,000,000 shares authorized; none issued or outstanding		-			-
Common stock, U.S. $0.01 par value; 1,200,000,000 shares authorized; issued and outstanding 303,757,622 at June 30, 2023 and at December 31, 2022								2,530			2,530
Preferred stock, U.S. $0.01 par value; 5,000,000 shares authorized; none-issued or outstanding								-			-
Additional paid-in capital		34,443			34,443			34,443			34,443
Accumulated deficit		(104,416	)		(102,555	)		(112,101	)		(102,555	)
Accumulated other comprehensive income		686			686			677			686
Total shareholders’ deficit		(66,757	)		(64,896	)		(74,451	)		(64,896	)
Total liabilities and shareholders’ deficit	E	7,324		E	7,321		€	533		€	7,321

The accompanying notes are an integral part of these condensed consolidated financial statements.

							For The Three Months Ended June 30,						For The Six Months Ended June 30,
	Three Months Ended March 31,						2023			2022			2023			2022
	2023			2022
Revenue
Research and development services	E	3		E	-
Advisory services		-			3
Grants revenue		274			482
Research and development							€	-		€	-		€	-		€	3
Grants								103			297			377			779
Other								-			-			3			3
		277			485			185			297			462			782
Expenses
Research and development		599			582			195			400			794			982
General and administrative		879			332			281			327			1,160			659
		1,478			914			476			727			1,954			1,641

Operating Loss		(1,201	)		(429	)		(291	)		(430	)		(1,492	)		(859	)

Interest expense		697			694			711			699			1,408			1,393
Other expense		(37	)		88
Goodwill impairment								6,671			-			6,671			-
Other (income) expense								94			213			57			301
								7,394			912			8,054			1,694

Loss before income tax provision		(1,861	)		(1,211	)		(7,685	)		(1,342	)		(9,546	)		(2,553	)

Income tax provision		-			-			-			-			-			-
Net Loss		(1,861	)		(1,211	)		(7,685	)		(1,342	)		(9,546	)		(2,553	)

Other comprehensive loss
Other comprehensive income
Foreign currency translation adjustment		-			7			(9	)		(2	)		(9	)		5
Comprehensive loss	E	(1,861	)	E	(1,204	)	€	(7,694	)	€	(1,344	)	€	(9,555	)	€	(2,548	)

Basic and diluted earnings per share	E	(0.00	)	E	(0.00	)

Weighted-average shares outstanding, basic and diluted		303,757,622			303,757,622			303,757,622			303,757,622			303,757,622			303,757,622

The accompanying notes are an integral part of these condensed consolidated financial statements.

Three-month Period Ended March 31, 2022

Three and Six-month Period Ended June 30, 2022

Common Stock

Number of Par

Accumulated

Accumulated Other Comprehensive

Common Stock

Number of Par

Accumulated

Accumulated Other Comprehensive

Value

APIC

Deficit

Income

Total

Value

APIC

deficit

Income

Total

Balance at December 31, 2021

303,757,622

2,530

34,443

(97,750

)

691

(60,086

)

303,757,622

2,530

34,443

(97,750

)

691

(60,086

)

Net loss

(1,211

)

(1,211

)

(1,211

)

(1,211

)

Translation adjustment

Balance at March 31, 2022

303,757,622

2,530

34,443

(98,961

)

698

(61,290

)

303,757,622

2,530

34,443

(98,961

)

698

(61,290

)

Net loss

(1,342

)

(1,342

)

Translation adjustment

)

Balance at June 30, 2022

303,757,622

2,530

34,443

(100,303

)

696

(62,634

)

Three-month Period Ended March 31, 2023

Three and six-month Period Ended June 30, 2023

Common Stock

Number of Par

Accumulated

Accumulated Other Comprehensive

Common Stock

Number of Par

Accumulated

Accumulated Other Comprehensive

Value

APIC

deficit

Income

Total

Value

APIC

deficit

Income

Total

Balance at December 31, 2022

303,757,622

2,530

34,443

(102,555

)

686

(64,896

)

303,757,622

2,530

34,443

(102,555

)

686

(64,896

)

Net loss

(1,861

)

(1,861

)

(1,861

)

(1,861

)

Translation adjustment

Balance at March 31, 2023

303,757,622

2,530

34,443

(104,416

)

686

(66,757

)

303,757,622

2,530

34,443

(104,416

)

698

(66,757

)

Net loss

(7,685

)

(7,685

)

Translation adjustment

)

Balance at June 30, 2023

303,757,622

2,530

34,443

(112,101

)

677

(74,451

)

The accompanying notes are an integral part of these condensed consolidated financial statements.

	For The Three Months Ended March 31,						For The Six Months Ended			For The Six Months Ended
	2023			2022			June 30, 2023			June 30, 2022
Cash Flow from Operating Activities
Net Loss	E	(1,861	)	E	(1,211	)
Net loss							€	(9,546	)	€	(2,553	)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation		3			5			6			8
Goodwill impairment								6,671			-
Gain on sales of equipment								(75	)		-
Changes in operating assets and liabilities
Receivables		(24	)		(396	)		20			(39	)
Accrued interests on convertible notes payable		578			707
Accrued interests on non-convertible notes payable		63			51
Accrued interest on convertible notes payable								1,215			1,557
Accrued interest on non-convertible notes payable								134			105
Accounts payable		758			376			446			31
Deferred grant								-			15
Other		5			14			47			52
Net cash used in operating activities		(478	)		(454	)		(1,082	)		(824	)

Cash Flows from Investing Activities
Proceeds from sale of equipment								92			-
Purchase of property and equipment		-			(2	)		-			(2	)
Net cash used in investing activities		-			(2	)		92			(2	)

Cash Flows from Financing Activities
Increase in notes payable		500			-
Repayments of federal bank loan								(12	)		-
Proceeds from issuance of non-convertible notes								1,100			600
Net cash provided by financing activities		500			-			1,088			600

Effect on foreign exchange rate on cash		-			7			(9	)		5
Net change in cash		22			(449	)		89			(221	)

Cash, beginning of period		313			571			313			571
Cash, end of period	E	335		E	122		€	402		€	350

Supplemental Disclosure of Cash Flow Information:
Cash paid for interest								-			-
Cash paid for taxes		-			-			-			-

The accompanying notes are an integral part of these condensed consolidated financial statements.

The amounts in the notes are shown in thousands of EURO, unless otherwise noted, and rounded to the nearest thousand except for share and per share amounts.

The accompanying interim period condensed consolidated financial statements of Mymetics Corporation (the "Company") set forth herein have been prepared by the Company pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (the "SEC"). Certain information and footnote disclosure normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted pursuant to such SEC rules and regulations. The interim period condensed consolidated financial statements should be read together with the audited financial statements and the accompanying notes included in the Company's latest annual report on Form 10-K for the fiscal year ended December 31, 2022.

The accompanying financial statements of the Company are unaudited. However, in the opinion of the Company, the unaudited condensed consolidated financial statements contained herein contain all adjustments necessary to present a fair statement of the results of the interim periods presented. All adjustments made during the three-month period ending March 31, 2023 were of a normal and recurring nature.

~~The~~ Company was created for the purpose of engaging in vaccine research and development. Its main research efforts in the beginning have been concentrated in the prevention and treatment of the AIDS virus and malaria. The Company has established a network which enables it to work with education centers, research centers, pharmaceutical laboratories and biotechnology companies. Besides the HIV and malaria vaccine candidates, the Company additionally has generated preclinical data for the following vaccines: Herpes Simplex and Respiratory Syncytial Virus (“RSV”), neither of which is currently being developed. The company also has clinical data for an intranasal influenza vaccine for the elderly which has finished a Phase I clinical trial and is currently on hold. As of ~~March 31,~~June 30, 2023, the Company ~~is working on several research projects~~has generated preclinical data for an intra nasal Covid-19 vaccine and early-stage preclinical data in immunotherapy in the field of oncology and for some infectious diseases with academic partners. Since April 2020, the Company has worked on the development of an intranasal virosome based vaccine to prevent Covid19, the disease caused by the SARSCoV2 virus. For the Covid19 vaccine candidates, theoncology. The Company has been collaborating with leading academic institutions, such as Baylor College of Medicine in Texas, the Amsterdam Medical Center (AMC) of the University of Amsterdam in the Netherlands and the University Hospital in Bern, ~~Switzerland.~~Switzerland until April 2023.

On January 16, 2023, the Board appointed Marcel B. Rüegg to the Board to fill the vacancy created by Mr. Stern’s resignation. Mr. Rüegg was also appointed to the Audit Committee. The Company entered into an independent director agreement with Mr. Rüegg (the “Director Agreement”) setting forth the terms of his compensation. Pursuant to the Director Agreement, Mr. Rüegg is entitled to a fee of CHF 5,000 per quarter, which is payable quarterly, and CHF 350 per hour for each additional hour worked outside of meetings of the Board or attending more than one meeting of the Board per quarter, which is payable quarterly. The Company also agreed to reimburse Mr. Rüegg for pre-approved reasonable business expenses incurred in good faith in connection with the performance of his duties for the Company. The Company also agreed to indemnify, defend and hold harmless Mr. Rüegg, to the fullest extent permitted by law, and as provided by, or granted pursuant to, any charter provision, bylaw provision, agreement, vote of stockholders or disinterested directors or otherwise, subject to certain exceptions based on good faith and reasonableness.

On February 8, 2023, the Company announced that it has been conducting a process to explore strategic alternatives to enhance shareholder value. The Board authorized management and its external advisors to initiate such a process, and it has been considering a broad range of strategic alternatives including a potential sale of part or all of the Company. In connection therewith, the Company, through its external advisors, ~~has~~had requested bids (the “Bid Process”) for any combination of assets (including but not limited to as a going concern), by February 24, 2023, at 5:00 pm ET (the “Bid Deadline”). To the extent the Company ~~determines~~determined there ~~are~~were viable bids by or prior to the Bid Deadline, the Company ~~anticipates pursuing~~pursued those ~~in due course.~~possible alternatives. To the extent the ~~Company determines~~ there ~~are~~were no viable bids provided by or prior to the Bid Deadline, the Company ~~may~~would consider other alternatives, including the winding up of its operations shortly after the Bid Deadline. On February 24, 2023, the Company announced that it iswas still discussing with counterparties potential bids for any combination of its assets (including but not limited to as a going concern) and ~~has~~had decided to extend the bid process (the “Bid Process”) for an indeterminate period of time. There can be no assurance that the Bid Process will result in the sale of part or all of the Company or other change or outcome. The Company has retained McDermott, Will & Emery LLP as legal counsel in connection with the Bid Process.

On May 12, 2023, the Company received an email from the OTC Markets Group compliance department notifying the Company that it no longer meets the Standards for Continued Eligibility for OTCQB as per the OTCQB Standards, Section 2.3(2), as a result of the closing bid price for the Company’s common stock being below $.01 per share on at least one of the prior thirty consecutive calendar days. As per Section 4.1 of the OTCQB Standards, the company will be granted a cure period of 90 calendar days during which the closing bid price for the Company’s common stock must be $0.01 or greater for ten consecutive trading days in order to continue trading on the OTCQB marketplace. If this requirement is not met by August 10, 2023, the company will be removed from the OTCQB marketplace. From June 21, 2023 until August 7, 2023, the closing bid price for the Company’s common stock was above $0.01, meeting the cure period requirement, however on August 8, 2023 the closing bid price dipped again below $0.01.

In addition, in the event that the Company’s closing bid price falls below $0.001 at any time for five consecutive trading days, the Company will be immediately removed from OTCQB.

The Board of Directors of the Company continues to evaluate the next steps, which could include a voluntary delisting of the OTCQB marketplace in connection with a possible winddown of the Company’s operations.

While the Company pursues these strategic alternatives, due to lack of liquidity, cost reductions for 2023 have been put in place, including the termination of employment agreements for all employees, except Ronald Kempers. ~~Additionally, we are exploring~~On July 26, 2023, the Company decided to wind down its wholly owned subsidiary Bestewil Holding BV (“BH”) and Mymetics BV, which is the wholly owned subsidiary of BH. BH has a ~~possible wind up~~remaining patent, which the Company expects to acquire to partially compensate for the approximate Euro 6 million accumulated intercompany loans from Mymetics Corporation to BH. The Company is working with the appropriate accountants to ensure this winddown process follows the applicable tax and accounting regulations. The execution of the ~~Company~~winddown is expected to take several months to complete and is subject to various risks and uncertainties that could impact on the Company's ability to successfully complete the winddown or the costs associated with the winddown. To the extent that none of the remaining strategic alternatives are ~~viable.~~viable, we are exploring a possible winddown of the Company. As of the date of this filing, there is no certainty or conclusion on the future of the Company.

These consolidated financial statements have been prepared assuming the Company will continue as a going ~~concern.~~concern, however the significantly reduced human resource and lack of financial resources has triggered the Company to record a complete Goodwill write-off for the period ending June 30, 2023. The Company has experienced negative cash flows from operations and significant losses since inception resulting in an accumulated deficit of ~~€104,416~~€112,101 at ~~March 31,~~June 30, 2023. Further, the Company’s current liabilities exceed its current assets by ~~€73,408~~€74,347 as of ~~March 31,~~June 30, 2023, and there is no assurance that cash will become available to pay current liabilities in the near term. Management is seeking ~~additional financing~~strategic alternatives but there can be no assurance that management will be successful in any of those efforts. These conditions raise substantial doubt about our ability to continue as a going concern within ~~one year~~three months of the issuance of the financial statements. ~~The~~Besides the Goodwill impairment, the financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Effective January 1, 2019, the Company adopted ASC 842, which established a right-of-use ("ROU") model requiring lessees to record a right-of-use ("ROU") asset and lease obligations on the balance sheet for all leases with terms longer than 12 months. The Company determines if an arrangement is a lease at inception. Where an arrangement is a lease, the Company determines if it is an operating lease or a finance lease. At lease commencement, the Company records a lease liability and corresponding right-of-use ("ROU") asset. Lease liabilities represent the present value of our future lease payments over the expected lease term, which includes options to extend or terminate the lease when it is reasonably certain those options will be exercised. The present value of the Company’s lease liability is determined using its incremental collateralized borrowing rate at lease inception. ROU assets represent its right to control the use of the leased asset during the lease and are recognized in an amount equal to the lease liability for leases with an initial term greater than 12 months. Over the lease term (operating leases only), the Company uses the effective interest rate method to account for the lease liability as lease payments are made and the ROU asset is amortized to consolidated statement of operations in a manner that results in straight line expense recognition. The Company does not apply lease recognition requirements for short-term leases. Instead, the Company recognizes payments related to these arrangements in the consolidated statement of operations as lease costs on a straight-line basis over the lease term.

The COVID-19 pandemic presented a substantial public health and economic challenge around the world and has affected our employees, communities and business operations, as well as the U.S. and European economy and financial markets. The full extent to which the COVID-19 pandemic will continue to directly or indirectly affect our business, results of operations and financial condition will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning COVID-19 and new variants of concern, the actions taken to contain or treat COVID-19, and its economic impact on local, regional, national and international markets.

To date, we have been able to continue our operations and do not anticipate any material interruptions in the foreseeable future due to the COVID-19 pandemic. However, we are continuing to assess the potential impact of the COVID-19 pandemic on our business and operations, including our supply chain and research activities. It is possible that the COVID-19 pandemic and response efforts may have an impact in the future on us and/or our third-party suppliers and contract manufacturing partners' ability to collaborate and manufacture our products.

The condensed consolidated financial statements include the accounts of the Company and its subsidiaries. Significant intercompany accounts and transactions have been eliminated.

In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and ~~Hedging—Contracts~~Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. Specifically, ASU 2020-06 simplifies accounting for the issuance of convertible instruments by removing major separation models required under current GAAP. In addition, the ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and simplifies the diluted earnings per share (EPS) calculation in certain areas. ASU 2020-06 will be effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, beginning in ~~the~~ fiscal years which begin after December 15, 2020. The FASB has specified that an entity should adopt the guidance as of the beginning of its annual fiscal year. The Company is currently evaluating the impact of the pending adoption of this new standard on its consolidated financial statements.

The Company translates non-Euro assets and liabilities of its subsidiaries at the rate of exchange at the balance sheet date. Revenues and expenses are translated at the average rate of exchange throughout the period. Unrealized gains or losses from these translations are reported as a separate component of comprehensive income. Transaction gains or losses are included in ~~general and administrative expenses~~foreign exchange (gain) loss in the consolidated statements of comprehensive loss. The translation adjustments do not recognize the effect of income tax because the Company expects to reinvest the amounts indefinitely in operations. The Company's reporting currency is the Euro because substantially all of the Company's activities are conducted in Europe.

~~We consider~~The Company considers all highly liquid investments purchased with maturities of ~~three~~six months or less to be cash equivalents. Cash deposits are occasionally in excess of insured amounts.

Effective January 1, 2018, the Company adopted Accounting Standards Codification (ASC) Topic 606, Revenue from Contracts with Customers, using the modified retrospective method and there was no impact to financial position and results of operations as a result of the adoption. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of Topic 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Overall, adoption of the new standard did not result in an adjustment to amounts previously reported in our consolidated financial statements and there were no other significant changes impacting the timing or measurement of our revenue or our business processes and controls.

The Company has concluded that government grants are not within the scope of Topic 606, as they do not meet the definition of a contract with a “customer”. The Company concluded the definition of a contract with a “customer” was not met as the counterparty to the government grants has not contracted to obtain goods or services and thus the contracts are not considered to have commercial substance. Government grants provide the Company with payments for certain types of expenditures related to research and development activities over a contractually defined period. Revenue from government grants is recognized in the period during which the related costs are incurred, provided that the applicable conditions under the government contracts have been met.

On April 29, 2019, the National Institutes of Health (“NIH”) awarded the Company and Texas Biomedical Research Institute (“Texas Biomed”) a five-year grant for the project called “Cold Chain-independent, Needle-free Mucosal Virosomal Vaccine to Prevent HIV-1 Acquisition at Mucosal Levels” (“NIH Grant”). The project started on May 1, 2019, and has been planned for five years. It was initially co-led by Texas Biomed, but due to the move of Dr. Ruth Ruprecht, the Co-Principal Investigator, to the University of Louisiana at Lafayette (“ULL”) at the end of 2019, ULL has become the co-lead with Mymetics for this project. The overall budget related to the project is US$8,850 with US$~~7,131~~8,761 approved for the period of (May 2019 to April ~~2023)~~2024). This includes the funds approved for the period of (May ~~2022~~2023 to April ~~2023)~~2024) of US$~~1,616.~~1’630.

The amounts mentioned in the following statements are purely related to the Company and not to the other partners in the project: The overall portion of the grant allocated to the Company is US$~~4,650~~4,052 approved for the period of (May 2019 to April ~~2023)~~2024). This includes the funds approved for the period of (May ~~2022~~2023 to April ~~2023)~~2024) of US$~~1,328.~~97. In March 2023, an amendment to the contract was signed to reduce the allocated funds from ULL to the Company from US$1,328 to US$ 815, as more funds were allocated to the animal studies at ~~ULL~~ULL.

The cost granted under the sub-award with Texas Biomed for the period of (May to December 2019) was US$743, of which, US$599 (€542) was incurred as revenue.

The sub-award contracts between ULL and the Company for the period of (January 2020 to April 2021) were signed for a total budget of US$~~1,519,~~1,319, of which, US$1,048 (€909) was incurred as revenue.

The sub-award contract between ULL and the Company for the period of (May 2021 to April 2022) was signed for a total budget of US$1,078, of which, US$986 (€899) was incurred as revenue.

The sub-award contract, including the amendment, between ULL and the Company for the period of (May 2022 to April 2023) was signed for a total budget of US$815, of which, US$~~577~~674 (€~~550)~~638) was incurred as revenue as of end of ~~March~~April 2023. ~~Of this revenue amount,~~

The sub-award contract between ULL and the Company for the period of (May 2023 to April 2024) was signed for a total budget of US$~~288~~97, of which, US$19 (€~~273)~~17) was ~~recognized during the three months ended March 31, 2023.~~incurred as revenue.

Since the beginning of the project to date, the Company has incurred a total cost of US$~~3,210~~3,326 (€~~2,900)~~3,005) which was recognized as grant revenue from the NIH. For the three and six months ended on June 30, 2023, the Company has incurred a total cost of US$116 (€106) and US$404 (€376), respectively, which was recognized as grant revenue from the NIH. The First results are expected to be reported in 2023.

The project has the objective to prepare the Company’s HIV-1 vaccine candidate for clinical trials, by first executing a non-human primate (“NHP”) study, where the test subjects will be receiving Mymetics’ virosome based HIV-1 vaccine candidate by several intra-muscular and intra-nasal applications, followed by rectal challenges. As of ~~March 31,~~June 30, 2023, Mymetics has successfully produced six sets of virosome based vaccines and the NHPs have received two intramuscular vaccinations and three intranasal vaccinations in two different studies. The vaccinations were well tolerated. ~~These~~The final studies are ongoing. The vaccine candidate is created to induce protective mucosal antibodies acting as a frontline defense against sexual HIV transmission. This grant from the NIH has allowed the Company to continue some of the developments that were achieved during the European Horizon 2020 project.

In February 2022, Mymetics announced the publication of results in Frontiers in Immunology title: “Cooperation between Systemic and Mucosal Antibodies Induced by Virosomal Vaccines Targeting HIV1 Env: Protection of Indian Rhesus Macaques against Mucosal SHIV challenges”.

Receivables are stated at their outstanding principal balances. Management reviews the collectability of receivables on a periodic basis and determines the appropriate amount of any allowance. There was no allowance necessary at ~~March 31,~~June 30, 2023 or December 31, 2022. The Company writes off receivables to the allowance when management determines that a receivable is not collectible. The Company may retain a security interest in the products sold.

Property and equipment is recorded at cost and is depreciated over its estimated useful life on straight-line basis from the date placed in service. Estimated useful lives are usually taken as three years.

Long-lived assets, which include property and equipment, are assessed for impairment whenever events or changes in circumstances indicate the carrying amount of the asset may not be recoverable. The impairment testing involves comparing the carrying amount to the forecasted undiscounted future cash flows generated by that asset. In the event the carrying value of the assets exceeds the undiscounted future cash flows generated by that asset and the carrying value is not considered recoverable, impairment exists. An impairment loss is measured as the excess of the asset’s carrying value over its fair value, calculated using a discounted future cash flow method. An impairment loss would be recognized in net income (loss) in the period that the impairment occurs.

Goodwill represents the excess of purchase price over the value assigned to the net tangible and identifiable intangible assets of a business acquired. The Company typically performs its annual goodwill impairment test effective as of April 1 of each year, unless events or circumstances indicate impairment may have occurred before that time. The Company assesses qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount. ~~After assessing qualitative factors,~~With the significantly reduced human resources and lack of funds the Company ~~determined that no further testing was necessary. If further testing was necessary,~~has recorded a complete Goodwill write-off for the ~~Company would determine the fair value of each reporting unit and compare the fair value to the reporting unit’s carrying amount. The Company has one reporting unit.~~period ending June 30, 2023.

The Company accounts for income taxes under an asset and liability approach that requires the recognition of deferred tax assets and liabilities for expected future tax consequences of events that have been recognized in the Company's financial statements or tax returns. In estimating future tax consequences, the Company generally considers all expected future events other than enactments of changes in the tax laws or rates.

The Company reports a liability, if any, for unrecognized tax benefits resulting from uncertain income tax positions taken or expected to be taken in an income tax return. Estimated interest and penalties, if any, are recorded as a component of interest expense and other expense, respectively.

The Company has not recorded any liabilities for uncertain tax positions or any related interest and penalties at December 31, 2022 or 2021. The Company’s United States tax returns are open to audit for the years ended December 31, 2018 to 2021. The returns for the Swiss subsidiary, Mymetics S.A., are open to audit for the year ended December 31, 2021. The returns for the Netherlands subsidiaries, Bestewil B.V. and Mymetics B.V., are open to audit for the year ended December 31, 2021.

Basic earnings per share is computed by dividing net income or loss attributable to common shareholders by the weighted average number of common shares outstanding in the ~~common~~ period. Diluted earnings per share takes into consideration common shares outstanding (computed under basic earnings per share) and potentially dilutive securities. For the ~~quarters~~periods ended ~~March 31,~~June 30, 2023 and 2022, options and convertible debt were not included in the computation of diluted earnings per share ~~under the treasury stock method~~ because their effect would be anti-dilutive due to net losses incurred under the ~~net loss.~~treasury stock method.

For the three and six months ended ~~March 31,~~June 30, 2023, the basic weighted and diluted average number of shares was 303,757,622. The total potential number of shares issuable of ~~811,823,576~~820,925,100 at ~~March 31,~~June 30, 2023 includes ~~786,073,576~~795,175,100 potential issuable shares related to convertible loans, and 25,750,000 potential issuable shares related to outstanding ~~not expired~~stock options granted to employees.

For the three and six months ended ~~March 31,~~June 30, 2022, the basic weighted and diluted average number of shares was 303,757,622. The total potential number of shares issuable of ~~775,330,552~~784,480,472 at ~~March 31,~~June 30, 2022 includes ~~749,580,552~~758,730,472 potential issuable shares related to convertible loans, and 25,750,000 potential issuable shares related to outstanding ~~not expired~~stock options granted to employees.

The Company has authorized 5,000,000 shares of preferred stock that may be issued in several series with varying ~~dividends,~~dividend, conversion and voting rights. No preferred shares are issued or outstanding at ~~March 31,~~June 30, 2023 or December 31, 2022.

The preparation of financial statements in conformity with United States generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Fair value guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:

The Company generally has the following financial instruments: cash, receivables, accounts payable, and notes payable. The carrying value of cash, accounts receivable, and accounts payable, approximates their fair value based on the short-term nature of these financial instruments. Management believes the fair value of the note’s payable ~~reflects~~is reflecting the actual value reported for these instruments.

The Company derived 99% of grant revenue for the ~~three-month period~~six-month periods ended ~~March 31,~~June 30, 2023 and 2022, respectively, from one ~~partner,~~grantor, respectively. For the period ended December 31, 2022, the Company derived 100% of grant revenue from one partner.

Mr. Ernest M. Stern, the Company’s, ~~outside U.S. counsel,~~ is a partner in Culhane Meadows PLLC and was outside counsel to the company and a director of the Company until his resignation on December 20, 2022. Culhane Meadows PLLC was the Company’s legal counsel until December 31, 2022. Fees incurred with the law firm was NIL in the ~~three~~six months ended ~~March 31, 2022, amounted to €17~~June 30, 2023, and ~~was NIL~~€33 for the ~~three~~six months ended ~~March 2023.~~June 2022.

Two of the Company’s major shareholders have granted secured convertible notes and short-term convertible notes and promissory notes, which have a total carrying amount of ~~€72,607,~~€73,675 including interest due ~~to date.~~as of June 30, 2023. Conversion prices on the Euro-denominated convertible debt have been fixed to a fixed Euro/US dollar exchange rate.

Certain principal shareholders have granted the Company secured convertible notes (in accordance with the Uniform Commercial Code in the State of Delaware), short term convertible notes and other short-term notes, which have a total carrying value of ~~€72,845~~€74,153 including interest due to date. Interest incurred inon these notes since inception has been added to the principal amounts.

The details of the convertible notes and loans are as follows at ~~March 31,~~June 30, 2023:

										Fixed										Fixed
								Conversion		Rate									Conversion	Rate
Lender	1st-Issue	Principal		Duration			Interest	Price		EUR/USD		1st-Issue	Principal		Duration		Interest		Price	EUR/USD
Price	Date	Amount		(Note)			Rate	(stated)		Conversion		Date	Amount		(Note)		Rate		(stated)	Conversion

Eardley Holding A.G. (1)	06/23/2006	E	175		(2	)	10% pa	$	0.10		N/A	06/23/2006	€	175	(2	)	10% pa	$	0.10	N/A
Anglo Irish Bank S.A.(3)	10/21/2007	E	500		(2	)	10% pa	$	0.50		1.4090	10/21/2007	€	500	(2	)	10% pa	$	0.50	1.4090
Round Enterprises Ltd.	12/10/2007	E	1,500		(2	)	10% pa	$	0.50		1.4429	12/10/2007	€	1,500	(2	)	10% pa	$	0.50	1.4429
Round Enterprises Ltd.	01/22/2008	E	1,500		(2	)	10% pa	$	0.50		1.4629	01/22/2008	€	1,500	(2	)	10% pa	$	0.50	1.4629
Round Enterprises Ltd.	04/25/2008	E	2,000		(2	)	10% pa	$	0.50		1.5889	04/25/2008	€	2,000	(2	)	10% pa	$	0.50	1.5889
Round Enterprises Ltd.	06/30/2008	E	1,500		(2	)	10% pa	$	0.50		1.5380	06/30/2008	€	1,500	(2	)	10% pa	$	0.50	1.5380
Round Enterprises Ltd.	11/18/2008	E	1,200		(2	)	10% pa	$	0.50		1.2650	11/18/2008	€	1,200	(2	)	10% pa	$	0.50	1.2650
Round Enterprises Ltd.	02/09/2009	E	1,500		(2	)	10% pa	$	0.50		1.2940	02/09/2009	€	1,500	(2	)	10% pa	$	0.50	1.2940
Round Enterprises Ltd.	06/15/2009	E	5,500		(2,4	)	10% pa	$	0.80		1.4045	06/15/2009	€	5,500	(2,4	)	10% pa	$	0.80	1.4045
Eardley Holding A.G.	06/15/2009	E	100		(2,4	)	10% pa	$	0.80		1.4300	06/15/2009	€	100	(2,4	)	10% pa	$	0.80	1.4300
Von Meyenburg	08/03/2009	E	200		(2	)	10% pa	$	0.80		1.4400	08/03/2009	€	200	(2	)	10% pa	$	0.80	1.4400
Round Enterprises Ltd.	10/13/2009	E	2,000		(2	)	5% pa	$	0.25		1.4854	10/13/2009	€	2,000	(2	)	5% pa	$	0.25	1.4854
Round Enterprises Ltd.	12/18/2009	E	2,200		(2	)	5% pa	$	0.25		1.4338	12/18/2009	€	2,200	(2	)	5% pa	$	0.25	1.4338
Round Enterprises Ltd.	08/04/2011	E	1,103		(5,6	)	10% pa	$	0.034		N/A	08/04/2011	€	1,102	(5,6	)	10% pa	$	0.034	N/A
Eardley Holding A.G.	08/04/2011	E	276		(5,6	)	10% pa	$	0.034		N/A	08/04/2011	€	276	(5,6	)	10% pa	$	0.034	N/A
Round Enterprises Ltd.	11/08/2011	E	400		(6	)	10% pa	$	0.034		1.3787	11/08/2011	€	400	(6	)	10% pa	$	0.034	1.3787
Eardley Holding A.G.	11/08/2011	E	100		(6	)	10% pa	$	0.034		1.3787	11/08/2011	€	100	(6	)	10% pa	$	0.034	1.3787
Round Enterprises Ltd.	02/10/2012	E	1,000		(6	)	10% pa	$	0.034		1.3260	02/10/2012	€	1,000	(6	)	10% pa	$	0.034	1.3260
Eardley Holding A.G.	02/14/2012	E	200		(6	)	10% pa	$	0.034		1.3260	02/14/2012	€	200	(6	)	10% pa	$	0.034	1.3260
Round Enterprises Ltd.	04/19/2012	E	322		(6	)	10% pa	$	0.034		1.3100	04/19/2012	€	322	(6	)	10% pa	$	0.034	1.3100
Eardley Holding A.G.	04/19/2012	E	80		(6	)	10% pa	$	0.034		1.3100	04/19/2012	€	80	(6	)	10% pa	$	0.034	1.3100
Round Enterprises Ltd.	05/04/2012	E	480		(6	)	10% pa	$	0.034		1.3152	05/04/2012	€	480	(6	)	10% pa	$	0.034	1.3152
Eardley Holding A.G.	05/04/2012	E	120		(6	)	10% pa	$	0.034		1.3152	05/04/2012	€	120	(6	)	10% pa	$	0.034	1.3152
Round Enterprises Ltd.	09/03/2012	E	200		(6	)	10% pa	$	0.034		1.2576	09/03/2012	€	200	(6	)	10% pa	$	0.034	1.2576
Eardley Holding A.G.	09/03/2012	E	50		(6	)	10% pa	$	0.034		1.2576	09/03/2012	€	50	(6	)	10% pa	$	0.034	1.2576
Round Enterprises Ltd.	11/14/2012	E	500		(6	)	10% pa	$	0.034		1.2718	11/14/2012	€	500	(6	)	10% pa	$	0.034	1.2718
Eardley Holding A.G.	12/06/2012	E	125		(6	)	10% pa	$	0.034		1.3070	12/06/2012	€	125	(6	)	10% pa	$	0.034	1.3070
Round Enterprises Ltd.	01/16/2013	E	240		(6	)	10% pa	$	0.034		1.3318	01/16/2013	€	240	(6	)	10% pa	$	0.034	1.3318
Eardley Holding A.G.	01/16/2013	E	60		(6	)	10% pa	$	0.034		1.3318	01/16/2013	€	60	(6	)	10% pa	$	0.034	1.3318
Round Enterprises Ltd.	03/25/2013	E	400		(6	)	10% pa	$	0.037		1.2915	03/25/2013	€	400	(6	)	10% pa	$	0.037	1.2915
Eardley Holding A.G.	04/14/2013	E	150		(6	)	10% pa	$	0.034		1.3056	04/14/2013	€	150	(6	)	10% pa	$	0.034	1.3056
Round Enterprises Ltd.	04/14/2013	E	600		(6	)	10% pa	$	0.034		1.3056	04/14/2013	€	600	(6	)	10% pa	$	0.034	1.3056
Eardley Holding A.G.	05/15/2013	E	170		(6	)	10% pa	$	0.037		1.2938	05/15/2013	€	170	(6	)	10% pa	$	0.037	1.2938
Round Enterprises Ltd.	05/15/2013	E	680		(6	)	10% pa	$	0.037		1.2938	05/15/2013	€	680	(6	)	10% pa	$	0.037	1.2938
Eardley Holding A.G.	06/24/2013	E	60		(6	)	10% pa	$	0.025		1.3340	06/24/2013	€	60	(6	)	10% pa	$	0.025	1.3340
Round Enterprises Ltd.	06/24/2013	E	240		(6	)	10% pa	$	0.025		1.3340	06/24/2013	€	240	(6	)	10% pa	$	0.025	1.3340
Eardley Holding A.G.	08/05/2013	E	80		(6	)	10% pa	$	0.018		1.3283	08/05/2013	€	80	(6	)	10% pa	$	0.018	1.3283
Round Enterprises Ltd.	08/05/2013	E	320		(6	)	10% pa	$	0.018		1.3283	08/05/2013	€	320	(6	)	10% pa	$	0.018	1.3283
Eardley Holding A.G.	03/01/2017	E	230		(7	)	2.5% pa		N/A		N/A	03/01/2017	€	230	(7	)	2.5% pa		N/A	N/A
Round Enterprises Ltd.	03/01/2017	E	920		(7	)	2.5% pa		N/A		N/A	03/01/2017	€	920	(7	)	2.5% pa		N/A	N/A
Eardley Holding A.G.	10/18/2017	E	230		(7	)	2.5% pa		N/A		N/A	10/18/2017	€	230	(7	)	2.5% pa		N/A	N/A
Round Enterprises Ltd.	10/18/2017	E	920		(7	)	2.5% pa		N/A		N/A	10/18/2017	€	920	(7	)	2.5% pa		N/A	N/A
Eardley Holding A.G.	06/01/2018	E	160		(8	)	2.5% pa		N/A		N/A	06/01/2018	€	160	(8	)	2.5% pa		N/A	N/A
Round Enterprises Ltd.	06/01/2018	E	640		(8	)	2.5% pa		N/A		N/A	06/01/2018	€	640	(8	)	2.5% pa		N/A	N/A
Eardley Holding A.G.	11/10/2018	E	160		(8	)	2.5% pa		N/A		N/A	11/10/2018	€	160	(8	)	2.5% pa		N/A	N/A
Round Enterprises Ltd.	11/10/2018	E	640		(8	)	2.5% pa		N/A		N/A	11/10/2018	€	640	(8	)	2.5% pa		N/A	N/A
Eardley Holding A.G.	06/15/2019	E	120		(9	)	2.5% pa		N/A		N/A	06/15/2019	€	120	(9	)	2.5% pa		N/A	N/A
Round Enterprises Ltd.	06/15/2019	E	480		(9	)	2.5% pa		N/A		N/A	06/15/2019	€	480	(9	)	2.5% pa		N/A	N/A
Eardley Holding A.G.	12/20/2019	E	120		(10	)	2.5% pa		N/A		N/A	12/20/2019	€	120	(10	)	2.5% pa		N/A	N/A
Round Enterprises Ltd.	12/20/2019	E	480		(10	)	2.5% pa		N/A		N/A	12/20/2019	€	480	(10	)	2.5% pa		N/A	N/A
Eardley Holding A.G.	06/15/2020	E	220		(11	)	2.5% pa		N/A		N/A
Eardley Holding AG												06/15/2020	€	220	(11	)	2.5% pa		N/A	N/A
Round Enterprises Ltd.	06/15/2020	E	880		(11	)	2.5% pa		N/A		N/A	06/15/2020	€	880	(11	)	2.5% pa		N/A	N/A
Eardley Holding A.G.	12/15/2020	E	170		(12	)	2.5% pa		N/A		N/A
Eardley Holding AG												12/15/2020	€	170	(12	)	2.5% pa		N/A	N/A
Round Enterprises Ltd.	12/15/2020	E	680		(12	)	2.5% pa		N/A		N/A	12/15/2020	€	680	(12	)	2.5% pa		N/A	N/A
Eardley Holding A.G.	08/15/2021	E	240		(13	)	2.5% pa		N/A		N/A
Eardley Holding AG												08/15/2021	€	240	(13	)	2.5% pa		N/A	N/A
Round Enterprises Ltd.												08/15/2021	€	960	(13	)	2.5% pa		N/A	N/A
Eardley Holding AG												04/30/2022	€	120	(14	)	2.5% pa		N/A	N/A
Round Enterprises Ltd.	08/15/2021	E	960		(13	)	2.5% pa		N/A		N/A	04/30/2022	€	480	(14	)	2.5% pa		N/A	N/A
Eardley Holding A.G.	04/30/2022	E	120		(14	)	2.5% pa		N/A		N/A	08/15/2022	€	120	(15	)	2.5% pa		N/A	N/A
Round Enterprises Ltd.	04/30/2022	E	480		(14	)	2.5% pa		N/A		N/A	08/15/2022	€	480	(15	)	2.5% pa		N/A	N/A
Eardley Holding A.G.	08/15/2022	E	120		(15	)	2.5% pa		N/A		N/A	12/31/2022	€	50	(16	)	2.5% pa		N/A	N/A
Round Enterprises Ltd.	08/15/2022	E	480		(15	)	2.5% pa		N/A		N/A	12/31/2022	€	200	(16	)	2.5% pa		N/A	N/A
Eardley Holding A.G.	12/31/2022	E	50		(16	)	2.5% pa		N/A		N/A	02/28/2023	€	100	(17	)	2.5% pa		N/A	N/A
Round Enterprises Ltd.	12/31/2022	E	200		(16	)	2.5% pa		N/A		N/A	02/28/2023	€	400	(17	)	2.5% pa		N/A	N/A
Eardley Holding A.G.	02/28/2023	E	100		(17	)	2.5% pa		N/A		N/A	05/30/2023	€	120	(18	)	2.5% pa		N/A	N/A
Round Enterprises Ltd.	02/28/2023	E	400		(17	)	2.5% pa		N/A		N/A	05/30/2023	€	480	(18	)	2.5% pa		N/A	N/A
Total Short Term Principal Amounts		E	38,031										€	38,630
Accrued Interest		E	34,814										€	35,523
TOTAL LOANS AND NOTES		E	72,845										€	74,153

(1) Private investment company of Dr. Thomas Staehelin, member of the Board of Directors and of the Audit Committee of the Company. Face value is stated in U.S. dollars at $190.

(2) This maturity date is automatically prolonged for periods of three months, unless called for repayment.

(3) Renamed Hyposwiss Private Bank Genève S.A. and acting on behalf of Round Enterprises Ltd. which is a major shareholder.

(4) The loan is secured against 2/3rds of the IP assets of Bestewil Holding BV and against all property of the Company.

(5) The face values of the loans are stated in U.S. dollars at $1,200 and $300, respectively.

(6) This maturity date is automatically prolonged for periods of three months, unless called for repayment. The conversion price per share is determined by the lower of (i) reducing by 10% the price per share of the Company’s common stock paid by the investors in connection with an investment in the Company of not less than US$20,000, or (ii) at the fixed conversion price using a fixed exchange rate which are noted in the table above. The convertible note holder has the right to convert at any time prior to the maturity date, at the convertible note holder’s option, prior to the repayment of the outstanding balance under the note by the Company, to convert the unpaid outstanding principal balance and accrued interest, in whole or in part, into common stock at the fixed conversion price as stated in the contract.

(7) On March 1, 2017, Round Enterprises Ltd. and Eardley Holding AG each provided two promissory Notes for a total of €1,840 and €460, respectively, with a 2.5% interest per annum and a maturity date of March 1, 2018. The first 50% of the promissory Notes of €920 and €230, respectively, were provided immediately. The second 50% of the promissory notes of €920 and €230, respectively, were provided on October 18, 2017, with a 2.5% interest per annum and a maturity date of October 18, 2018. Both Round Enterprises Ltd. And Eardley Holding AG have agreed to amend the maturity date of these promissory notes to follow the same terms of the other convertible loans. Therefore, the maturity date of the promissory notes is amended to be the later of (i) June 30, 2018, or (ii) the end of a subsequent calendar quarter in which the Company receives a written request from the lender for repayment of the unpaid principal and accrued interest due under the Notes. The amendments were accounted for as modifications in the consolidated financial statements.

(8) On June 1, 2018, Round Enterprises Ltd. and Eardley Holding AG each provided two promissory Notes for a total of €1,280 and €320 in two tranches, respectively, with a 2.5% interest per annum. The first tranche of the promissory Notes of €640 and €160, respectively, were provided immediately. The second tranche of the promissory notes of €640 and €160, respectively, were provided on November 10, 2018, with a 2.5% interest per annum. The maturity date of these promissory notes to follow the same terms of other convertible loans and is the later of (i) June 30, 2019, or (ii) the end of a subsequent calendar quarter in which the Company receives a written request from the lender for repayment of the unpaid principal and accrued interest due under the Notes.

(9) On June 15, 2019, Round Enterprises Ltd. and Eardley Holding AG each provided promissory Notes for a total of €600 with a 2.5% interest per annum. The promissory Notes of €480 and €120, respectively, were provided immediately. The maturity date of these promissory notes to follow the same terms of other convertible loans and is the later of (i) December 31, 2020, or (ii) the end of a subsequent calendar quarter in which the Company receives a written request from the lender for repayment of the unpaid principal and accrued interest due under the Notes.

(10) On December 20, 2019, Round Enterprises Ltd. and Eardley Holding AG each provided promissory Notes for a total of €600 with a 2.5% interest per annum. The promissory Notes of €480 and €120, respectively, were provided immediately. The maturity date of these promissory notes to follow the same terms of other convertible loans and is the later of (i) June 30, 2020, or (ii) the end of a subsequent calendar quarter in which the Company receives a written request from the lender for repayment of the unpaid principal and accrued interest due under the Notes.

(11) On June 15, 2020, Round Enterprises Ltd. and Eardley Holding AG each provided promissory Notes for a total of €1,100 with a 2.5% interest per annum. The promissory Notes of €880 and €220, respectively, were provided immediately. The maturity date of these promissory notes to follow the same terms of other convertible loans and is the later of (i) September 30, 2020, or (ii) the end of a subsequent calendar quarter in which the Company receives a written request from the lender for repayment of the unpaid principal and accrued interest due under the Notes.

(12) On December 15, 2020, Round Enterprises Ltd. and Eardley Holding AG each provided promissory Notes for a total of €850 with a 2.5% interest per annum. The promissory Notes of €680 and €170, respectively, were provided immediately. The maturity date of these promissory notes to follow the same terms of other convertible loans and is the later of (i) March 31, 2021, or (ii) the end of a subsequent calendar quarter in which the Company receives a written request from the lender for repayment of the unpaid principal and accrued interest due under the Notes.

(13) On August 15, 2021, Round Enterprises Ltd. and Eardley Holding AG each provided promissory Notes for a total of €1,200 with a 2.5% interest per annum. The promissory Notes of €960 and €240, respectively, were provided immediately. The maturity date of these promissory notes to follow the same terms of other convertible loans and is the later of (i) December 31, 2021, or (ii) the end of a subsequent calendar quarter in which the Company receives a written request from the lender for repayment of the unpaid principal and accrued interest due under the Notes.

(14) On April 30, 2022, Round Enterprises Ltd. and Eardley Holding AG each provided two promissory Notes for a total of ~~€600~~€960 and €240 in two tranches, respectively, with a 2.5% interest per annum. The first tranche of the promissory Notes of €480 and €120, respectively, were provided immediately. The second tranche of the promissory notes of €480 and €120, respectively, will be provided in August, 2022, with a 2.5% interest per annum. The maturity date of these promissory notes to follow the same terms of other convertible loans and is the later of (i) September 30, 2022, or (ii) the end of a subsequent calendar quarter in which the Company receives a written request from the lender for repayment of the unpaid principal and accrued interest due under the Notes.

(15) On August 15, 2022, Round Enterprises Ltd. and Eardley Holding AG each provided promissory Notes for a total of €600 with a 2.5% interest per annum. The promissory Notes of €480 and €120, respectively, were provided immediately. The maturity date of these promissory notes to follow the same terms of other convertible loans and is the later of (i) December 31, 2022, or (ii) the end of a subsequent calendar quarter in which the Company receives a written request from the lender for repayment of the unpaid principal and accrued interest due under the Notes.

(16) On December 31, 2022, Round Enterprises Ltd. and Eardley Holding AG each provided promissory Notes for a total of €250 with a 2.5% interest per annum. The promissory Notes of €200 and €50, respectively, were provided immediately. The maturity date of these promissory notes to follow the same terms of other convertible loans and is the later of (i) March 31, 2023, or (ii) the end of a subsequent calendar quarter in which the Company receives a written request from the lender for repayment of the unpaid principal and accrued interest due under the Notes.

(17) On February 28, 2023, Round Enterprises Ltd. and Eardley Holding AG each provided promissory Notes for a total of €500 with a 2.5% interest per annum. The promissory Notes of €400 and €100, respectively, were provided immediately. The maturity date of these promissory notes to follow the same terms of other convertible loans and is the later of (i) June 30, 2023, or (ii) the end of a subsequent calendar quarter in which the Company receives a written request from the lender for repayment of the unpaid principal and accrued interest due under the Notes.

(18) On May 30, 2023, Round Enterprises Ltd. and Eardley Holding AG each provided promissory Notes for a total of €600 with a 2.5% interest per annum. The promissory Notes of €480 and €120, respectively, were provided immediately. The maturity date of these promissory notes to follow the same terms of other convertible loans and is the later of (i) September 30, 2023, or (ii) the end of a subsequent calendar quarter in which the Company receives a written request from the lender for repayment of the unpaid principal and accrued interest due under the Notes.

On April 2, 2020, the Swiss entity, Mymetics SA, received a federal credit line of Chf 168 in relation with the Covid-19 pandemic. This credit line applies for five years and is fully guaranteed by the Swiss Confederation via guaranteed organizations. The interest rate is currently at 0 percent until March 31, 2023. The Swiss Confederation has the right to adjust the interest rate to the market rate. The first revision took place as of April 1, 2022, but no modification was applied. The second revision took place as of April 13, 2023, and decided to introduce an interest rate of 1.5% per year as of April 1, 2023, which triggered an interest amount paid of €0.5 on June 30, 2023.

A first amortization installment of Chf 14 (€14) was paid on October 3, 2022. A second amortization installment of Chf 14 (€14) was paid on April 3, 2023. The next amortization of €14 is due on ~~March 31,~~September 30, 2023, but will be settled in ~~April~~October 2023. The entire loan should be fully amortized and repaid by September 30, 2027.

Certain of the secured convertible notes have conversion features that should be bifurcated from the debt and recorded at fair value; however, as of ~~March 31,~~June 30, 2023, and 2022, the probability of the conversion features being exercised was zero. For this reason, the conversion features is not required to be bifurcated from the debt as the fair value is zero at ~~March 31,~~June 30, 2023 and December 31, 2022.

The facility lease agreement for Epalinges, Switzerland, is automatically renewed month by month with a notice period of three months. The related rent is paid monthly in the amount of €4 and is considered a short-term lease. As the term is less than twelve months, the lease is outside of the scope of ASC 842 and not accounted for on the balance sheet due to the Company’s policy elections.

The facility lease agreement for Leiden, The Netherlands, runs until March 31, 2024, and can be terminated with a six-month notice as of September 30, 2023. On March 14, 2023, the Company terminated the facility lease agreement with ~~the~~an effective date negotiated to September 30, 2023 instead of March 31, 2024. The related rent is paid monthly in the amount of €9. The Company does not have any other operating lease for its research and development facilities, corporate headquarters, offices and equipment.

ASU 201602 and ASU 201811— Accounting Standards Update (“ASU”) 201602, Leases (“ASU 201602”) required the recognition of right-of-use lease assets relate primarily to the Company’s leases of office and laboratory space. Right-of-use lease assets initially equal the lease liability. The lease liability equals the present value of the minimum rental payments due under the lease discounted at the rate implicit in the lease or the Company’s incremental borrowing rate for similar collateral. For operating leases, lease liabilities were discounted at the Company’s weighted average incremental borrowing rate for similar collateral estimated to be 5% and the weighted average lease term is ~~2.25~~2 years. For operating leases, rent expense is recognized on a straight-line basis over the term of the lease and is recorded in “General and administrative” in the Company’s consolidated statements of operations. During the three and six months ended ~~March 31,~~June 30, 2023, the Company recognized ~~€0.2~~-€3 and -€3, respectively, in “General and administrative” in its consolidated statement of operations relating to operating ~~leases.~~leases as a result of the right-of-use lease assets write off.

On ~~May 12,~~July 4, 2023, the office lease agreement for Epalinges has been terminated as of August 31, 2023, and the Company is leasing a shared office space on a three month’s lease basis.

On July 26, 2023, the Company ~~received an email from~~decided to wind down its wholly owned subsidiary Bestewil Holding BV (“BH”) and Mymetics BV, which is the ~~OTC Markets Group compliance department notifying~~wholly owned subsidiary of BH. BH has a remaining patent, which the Company ~~that it no longer meets~~expects to acquire to partially compensate for the ~~Standards for Continued Eligibility for OTCQB as per~~approximate Euro 6 million accumulated intercompany loans from Mymetics Corporation to BH. The Company is working with the ~~OTCQB Standards, Section 2.3(2), as a result~~appropriate accountants to ensure this wind down process follows the applicable tax and accounting regulations. The execution of the closing bid price for the Company’s common stock being below $.01 per share on at least one of the prior thirty consecutive calendar days. As per Section 4.1 of the OTCQB Standards, the company will be granted a cure period of 90 calendar days during which the closing bid price for the Company’s common stock must be $0.01 or greater for ten consecutive trading days in order to continue trading on the OTCQB marketplace. If this requirement is not met by August 10, 2023, the company will be removed from the OTCQB marketplace.

In addition, the Company has been informed that in the event that the Company’s closing bid price falls below $0.001 at any time for five consecutive trading days, the Company will be immediately removed from OTCQB.

~~The Board of Directors of the Company will evaluate the next steps, which could include a voluntary delisting of the OTCQB marketplace in connection with a possible~~ wind down ofis expected to take several months to complete and is subject to various risks and uncertainties that could impact the ~~Company’s operations.~~Company's ability to successfully complete the wind down or the costs associated with the wind down.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of the results of operations and financial condition of Mymetics Corporation for the periods ended ~~March 31,~~June 30, 2023 and 2022 should be read in conjunction with the Company's audited consolidated financial statements for the year ended December 31, 2022 and related notes and the description of the Company's business and properties included elsewhere herein.

This report contains forward-looking statements that involve risks and uncertainties. The statements contained in this report are not purely historical but are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These forward-looking statements concern matters that involve risks and uncertainties that could cause actual results to differ materially from those projected in the forward-looking statements. Words such as "may," "will," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue", "probably" or similar words are intended to identify forward looking statements, although not all forward-looking statements contain these words.

Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity performance or achievements. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. We are under no duty to update any of the forward-looking statements after the date hereof to conform such statements to actual results or to changes in our expectations.

Readers are urged to carefully review and consider the various disclosures made by us which attempt to advise interested parties of the factors which affect our business, including without limitation disclosures made under the captions "Management Discussion and Analysis of Financial Condition and Results of Operations," "Risk Factors," "Consolidated Financial Statements" and "Notes to Consolidated Financial Statements" included in our annual report on Form 10-K for the year ended December 31, 2022 and, to the extent included therein, our quarterly reports on Form 10-Q filed during fiscal year 2023.

The COVID-19 pandemic has presented a substantial public health and economic challenge around the world and has is affecting our employees, patients, communities and business operations, as well as the U.S. and European economy and financial markets. The full extent to which the COVID-19 pandemic will continue to directly or indirectly affect our business, results of operations and financial condition will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning COVID-19 and new variants of concern, the actions taken to contain or treat COVID-19, and its economic impact on local, regional, national and international markets.

To date, we have been able to continue our operations and do not anticipate any material interruptions for the foreseeable future due to the COVID-19 pandemic. However, we are continuing to assess the potential impact of the COVID-19 pandemic on our business and operations, including our supply chain and research activities. It is possible that the COVID-19 pandemic and response efforts may have an impact in the future on us and/or our third-party suppliers and contract manufacturing partners' ability to collaborate and manufacture our products.

For the three months ended ~~March 31,~~June 30, 2023, revenue was €185, which includes €82 of gain on sales of laboratory equipment in Leiden, and €103, related to the revenue recognized for the work performed under the NIH grant / HIV project. For the three months ended June 30, 2022, revenue was €297, which was related to the revenue recognized for the work performed under the NIH grant / HIV project.

Costs and expenses decreased to €476 for the three months ended June 30, 2023 from €727 (-34.5%) for the three months ended June 30, 2022, of which:

Interest expense increased to €711 for the three months ended June 30, 2023 from €699 for the three months ended June 30, 2022 related to an increase in existing loans from related parties.

The significantly reduced human resources and available financial funds has triggered Goodwill write-off and an impairment of €6,671 which was recorded for the three months ended June 30, 2023 compared to €0 for the three months ended June 30, 2022.

Foreign exchange revaluation, recorded in Other (income) expense, generated a net gain of €1 and net loss of (€196) during the three months ended June 30, 2023 and 2022, respectively, which was due to the revaluation of existing US$ based loans from related parties and US$ cash position reflecting the a stable US$ with respect to the Euro during this three months period in 2023.

The Company reported a net loss of (€7,685), or (€0.00) per share, for the three months ended June 30, 2023, compared to a net loss of (€1,342), or (€0.00) per share, for the three months ended June 30, 2022.

For the six months ended June 30, revenue was ~~€277~~€462, which includes €82 of gain on sales of laboratory equipment in Leiden, and ~~€485, respectively, of~~€377, related to the revenue recognized for the work performed under the NIH grant / HIV project. For the six months ended June 30, 2022, revenue was €782, which ~~€274 and €482~~ was mainly related to the revenue recognized for the work performed under the NIH grant / HIV project.

Costs and expenses increased to ~~€1,478~~€1,954 for the ~~three~~six months ended ~~March 31,~~June 30, 2023 from ~~€914 (+61.7%~~€1,641 (19.1%) for the ~~three~~six months ended ~~March 31, 2022. The increase is mainly due the severance cost provision triggered by the termination~~June 30, 2022, of employment agreements at the end of February 2023 for a total of €674, and additional advisory and legal costs related to the Bid Process for a total of €200 incurred during the three months ended March 31, 2023.

Research and development expenses remained stable at €599 in the current period from €582 (+2.9%) in the comparative period of 2022, mainly due to the purchase of the influenza inactivated virus cost related to the work performed under the NIH grant / HIV project (-€302) incurred during the three months ended March 31, 2022, and €345 of severance cost provision triggered by the termination of employment agreements announced end of February 2023 for a total of €345.which:

~~General~~The Goodwill impairment of €6,671 was recorded for the six months ended June 30, 2023 compared to €0 for the six months ended June 30, 2022.

Foreign exchange revaluation, recorded in Other (income) expense, generated a net gain of €54 and ~~administrative expenses increased to €879 in~~a net loss of (€266) during the ~~current period from €332 (+164.8%) in the comparative period of~~six months ended June 30, 2023 and 2022, ~~mainly~~respectively, which is due to the ~~severance cost provision for a total~~revaluation of ~~€360,~~existing US$ based loans from related parties and ~~additional incurred advisory and legal costs related~~US$ cash position, reflecting the strong US$ in relation to the ~~Bid Process for a total of €200 during the three months ended March 31, 2023.~~

Other expenses decreased to -€37 for the three months ended March 31, 2023, from €88 (-142.0%) for the three months ended March 31, 2022, mainly due to the foreign exchange revaluation impact of shareholders’ loans based in US$.

~~Interest expenses increased to €697 for the three months ended March 31, 2023, from €694 for the three months ended March 31, 2022 related to existing loans from third party investors.~~Euro.

The Company reported a net loss of (€~~1,861)~~9,546), or (€~~0.00)~~0.01) per share, for the ~~three~~six months ended ~~March 31,~~June 30, 2023, compared to a net loss of (€~~1,211)~~2,553), or (€~~0.00)~~0.01) per share, for the ~~three~~six months ended ~~March 31,~~June 30, 2022.

We had cash of ~~€335~~€402 at ~~March 31,~~June 30, 2023 compared to €313 at December 31, 2022.

During 2022, our revenue has mainly been generated through the NIH grant / HIV project. For 2023, ~~besides revenue to be recognized under the NIH grant project,~~ new significant revenues are not ~~expected, unless and until a major licensing agreement or other commercial arrangement is entered into with respect to our technology or new grant financings are awarded.~~expected.

As of ~~March 31,~~June 30, 2023, we had an accumulated deficit of approximately ~~€104,416,~~€112 million, and had net loss of ~~€1,861~~€9,546 in the ~~three-month~~six-month period ending on that date. We expect to continue to incur net losses in the future for research, development and activities related to the future licensing of our technologies, and because of the accrual of interest payable on existing loans.

Net cash used from operating activities ~~decreased~~increased to ~~€478~~€1,082 for the ~~three-month~~six-month period ended ~~March 31,~~June 30, 2023, compared to ~~€454~~€824 for the same period in 2022, mainly due to the receivable related to the NIH grant / HIV project incurred during the ~~three-month~~six-month period ending ~~March 31, 2022.~~June 30, 2022, and the severance due as of June 30, 2023 of €682, of which, €178 has been paid in June 2023.

Net cash ~~used from~~provided in investing activities was ~~NIL~~€92 during the ~~three months~~six-months ended ~~March 31,~~June 30, 2023, due to sales of office equipment in Leiden, and ~~€(-2)~~€2 used during the same period in 2022, ~~mainly due~~related to ~~acquisition of~~new IT ~~equipment.~~equipment in Epalinges.

Net cash provided from financing activities ~~was €500~~€1,088 for the ~~three months~~six-months ended ~~March 31,~~June 30, 2023 and ~~NIL~~€600 for the ~~same period in 2022.~~six-months ended June 30, 2022, mainly related to new promissory notes from our main investors.

Salaries and related payroll costs represent gross salaries for two executives, our CSO of Mymetics BV and five employees. Under Executive Employment Agreements with our CEO and two CSOs, we pay our executive officers a combined amount of €65 per month.

Our Swiss subsidiary, Mymetics S.A., has, besides the CEO, ~~and CSO,~~ two additional employees on its payroll: Director of Finance and Head of Manufacturing and ~~Quality.~~Quality, the CSO is terminated as of May 31, 2023. All employees at Mymetics BV ~~has, besides the~~are terminated as of June 30, 2023 (the full time Chief Scientific Officer ~~three~~and one full-time ~~technicians~~technician on June 30, 2023; one full-time technician on May 31, 20236 and one part-time ~~assistant.~~assistant on April 30, 2023).

On February 8, 2023, and subsequently on February 23, 2023, we announced that we ~~have~~ initiated a process to explore a range of strategic alternatives to maximize shareholder value and engaged professional advisors, including an investment bank, to support this process. Strategic alternatives include the sale of all or part of the Company, through a merger or reverse merger. As we ~~pursue~~have been pursuing these strategic alternatives, we put into place cost reductions for 2023, including the termination of employment agreements with 7 of our 8 ~~employees~~employees. On July 26, we announced the winddown of the Company’s subsidiary in the Netherlands and are exploring a possible ~~wind up~~winddown of the Company to the extent that none of the strategic alternatives are viable.

Additional funding requirements during the next 93 to 6 months will be needed. In the past, we have financed our research and development activities primarily through debt and equity financings from various parties, complemented by the grant agreements for our HIV vaccine candidate.

We are seeking strategic alternatives for the Company, including the sale of all or part of the Company, ~~in parallel we seek to raise the additional capital from equity or debt financings, and grants through donors~~ and potential partnerships with major international pharmaceutical and biotechnology firms. However, there can be no assurance that itthe Company will be able to raise additional capital on satisfactory terms, or at all, to finance its remaining operations or sell the Company. In the event that we are not able to obtain such additional capital, we will be required to further restrict or even cease our operations. As discussed in Note 1 to the consolidated financial statements, the Company has experienced recurring losses from operations and negative cash flows from operating activities. These conditions raise substantial doubt about the Company's ability to continue as a going concern.

Monthly fixed and recurring expenses for "Property leases" of €13 represent the monthly lease and maintenance payments to unaffiliated third parties for our offices, of which €4 is related to our executive office located at Route de la Corniche 4, 1066 Epalinges in Switzerland (100 square meters), which have been terminated at the end of August 2023 and €9 related to Bestewil Holding B.V. and its subsidiary Mymetics B.V operating from a similar biotechnology campus near Leiden in the Netherlands, where they occupy 204 square ~~meters.~~meters, which has been terminated at the of September 2023.

Included in the professional fees are legal fees paid to outside corporate counsel and audit and review fees paid to our independent accountants, and fees paid for investor relations.

Cumulative interest expense of ~~€34,814~~€35,523 has been accrued on all of the Company’s outstanding notes and advances (see detailed table in Note 2 to the financial statements).

During the ~~three months~~six-month period ending ~~March 31,~~June 30, 2023, our principal source of funds has been promissory notes received from our two main investors and the revenue generated through the NIH grant / HIV project.

Management anticipates that our existing capital resources will be sufficient to fund our cash requirements through the next two months. We have cash presently on hand in conjunction with the collection of receivables, based upon our current levels of ~~expenditures~~expenditure and anticipated needs during this period. For 2023, we will need additional funding through future collaborative arrangements, licensing arrangements, a sale of all or part of the Company and debt and equity financings under Regulation D and Regulation S under the Securities Act of 1933. We do not know whether additional financing will be available when needed or if a sale will be successful.

Fluctuations in interest rates may affect the fair value of financial instruments. An increase in market interest rates may increase interest payments and a decrease in market interest rates may decrease interest payments of such financial instruments. We have no debt obligations, which are sensitive to interest rate fluctuations as all our notes payable have fixed interest rates, as specified on the individual loan notes.

Under the supervision and with the participation of the Company’s management, including its Chief Executive Officer and Chief Financial Officer the Company conducted an evaluation of the effectiveness of the Company’s disclosure controls and procedures, as defined in Rule 13a−15(e) and ~~15d-15(e)~~15d15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”), as of the end of the period covered by this ~~annual~~ report. Based on this evaluation, the Company’s Chief Executive Officer and Chief Financial Officer (currently the same person to allow timely decisions regarding required disclosure) concluded as of ~~March 31,~~June 30, 2023, that the Company’s disclosure controls and procedures were not effective because of the material weakness described below.

Management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act). Our internal control over financial reporting includes policies and procedures designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external reporting purposes in accordance with generally accepted accounting principles.

Under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, our management conducted an evaluation of the effectiveness of our internal control over financial reporting as of ~~March 31,~~June 30, 2023, based on the criteria established in Internal Control -- Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.

There have been no changes in our internal control over financial reporting during the quarter ended ~~March 31,~~June 30, 2023, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Our management, including the CEO/CFO, does not expect that the Disclosure Controls or our internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within our Company have been detected.

These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions of deterioration in the degree of compliance with policies or procedures.

Neither we, nor our wholly owned subsidiaries, Mymetics S.A., and Bestewil Holding B.V., nor its subsidiary Mymetics B.V., are presently involved in any litigation incident to our business.

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Level 1-	Quoted prices in active markets for identical assets or liabilities.
	Level 2-	Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or ~~liabilities;~~abilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by ~~observable~~servable market data for substantially the full term of the assets or liabilities.
	Level 3-	Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the ~~assets~~sets or liabilities.

31.1		Rule 13a-14(a)/15d-14(a) Certification of Chief

31.2		Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer

32		Section 1350 Certification of Chief Executive Officer and Chief Financial Officer

~~101.INS~~101.		INS Instance Document

~~101.SCH~~101.		SCH XBRL Taxonomy Extension Schema Document

~~101.CAL~~101.		CAL XBRL Taxonomy Extension Calculation Linkbase Document

~~101.LAB~~101.		LAB XBRL Taxonomy Extension Label Linkbase Document

~~101.PRE~~101.		PRE XBRL Taxonomy Extension Presentation Linkbase Document

	MYMETICS CORPORATION

Dated: ~~May 15,~~August 18, 2023	By:	/s/ Ronald Kempers
		Chief Executive Officer / Chief Financial Officer
		(Principal Executive, Financial and Accounting Officer)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the quarterly period ended ~~March 31,~~June 30, 2023

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the transition period from __________ to _________

~~Large accelerated~~Large-accelerated filer	☐	Accelerated filer	☐

Non-accelerated Filer	☒	Smaller reporting company	☒

		Emerging growth company	☐

	o	Research and development expenses decreased to €195 in the current period from €400 (-51.3%) in the comparative period of 2022, mainly due to significant reduced subcontracting services in relation with the NIH grant / HIV project compared to the expenses incurred during the three-month period ending June 2022.

	o	General and administrative expenses decreased to €281 in the three months ended June 30, 2022 from €327 (-14.1%) in the comparative period of 2022, mainly due €27 incurred during the three months ended June 30, 2022 related to the engagement as of May 2022 of consultants that assisted in seeking business development opportunities for the Company with the goal of obtaining deals for licensing, financing, and/or acquisition.


16 o	Research and development expenses decreased to €794 in the current period from €982 (-19.1%) in the comparative period of 2022, mainly due to the purchase of “influenza inactivated virus” during the first quarter in 2022 in relation with the NIH grant / HIV project, and €347 severance payments incurred during the six months ended June 30, 2023, of which, €178 has been paid in June 2023.

	o	General and administrative expenses increased to €1,160 in the six months ended June 30, 2023 from €659 (76.0%) in the comparative period of 2022, mainly due the accrual of €329 for severance, and €108 additional legal service incurred during the six months ended June 30, 2023.